Neuropathic pain: Mechanism-based therapeutics

Kirsty Bannister*, Juliane Sachau, Ralf Baron, Anthony H. Dickenson

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

121 Citations (Scopus)

Abstract

Neuropathic pain (NeP) can result from sources as varied as nerve compression, channelopathies, autoimmune disease, and incision. By identifying the neurobiological changes that underlie the pain state, it will be clinically possible to exploit mechanism-based therapeutics for maximum analgesic effect as diagnostic accuracy is optimized. Obtaining sufficient knowledge regarding the neuroadaptive alterations that occur in a particular NeP state will result in improved patient analgesia and a mechanism-based, as opposed to a disease-based, therapeutic approach to facilitate target identification. This will rely on comprehensive disease pathology insight; our knowledge is vastly improving due to continued forward and back translational preclinical and clinical research efforts. Here we discuss the clinical aspects of neuropathy and currently used drugs whose mechanisms of action are outlined alongside their clinical use. Finally, we consider sensory phenotypes, patient clusters, and predicting the efficacy of an analgesic for neuropathy.

Original languageEnglish
Pages (from-to)257-274
Number of pages18
JournalANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY
Volume60
Issue number1
DOIs
Publication statusPublished - 6 Jan 2020

Keywords

  • clinical targets
  • neurobiology
  • neuropathic pain
  • neuropathy
  • patient clusters
  • sensory phenotypes

Fingerprint

Dive into the research topics of 'Neuropathic pain: Mechanism-based therapeutics'. Together they form a unique fingerprint.

Cite this